Suvretta Capital Management
Overview
Suvretta Capital Management, LLC was formed in 2011 by Aaron Cowen . Suvretta Capital manages a generalist long/short equity strategy, which began investing on September 1, 2012, and two healthcare-focused long/short equity strategies . The firm employs a global equity strategy, utilizing both long and short positions, that incorporates fundamental analysis, "industry before company" investing, trading, options, risk control management, and an understanding of macro influences on equities . They primarily use equities, futures, ETFs, and equity options to express their investment opinions, preferring to use equity securities and options to hedge risk or enhance their view in a cost-efficient manner .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Veradermics Inc. | Oct 2025 | Series C | Co-investor |
| Avalyn Pharma | Jul 2025 | Series D | Lead |
| Veradermics Inc. | Dec 2024 | Series B | Lead |
| connectRN | Dec 2021 | Series B | Lead |
| Freenome | Dec 2021 | Series D | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.